35166-78-0 Usage
Uses
Different sources of media describe the Uses of 35166-78-0 differently. You can refer to the following data:
1. Reactant involved in:Isomerization polymerization of alkenylcyclohexanesIntramolecular rearrangements of vinylidenecyclopropanesCycloisomerization of cyclic and acyclic enynesAdditionally reactant involved in synthesis of biologically active molecules including:Dipeptidyl boronic acid proteasome inhibitorsSubstituted 1,3-dihydroindole-2-ones with antitumor effectsSulfur-free transition state nucleoside analog inhibitors of methylthioadenosine nucleosidase and phosphorylase
2. Reactant involved in:? ;Isomerization polymerization of alkenylcyclohexanes1? ;Intramolecular rearrangements of vinylidenecyclopropanes2? ;Cycloisomerization of cyclic and acyclic enynes3Additionally reactant involved in synthesis of biologically active molecules including:? ;Dipeptidyl boronic acid proteasome inhibitors4? ;Substituted 1,3-dihydroindole-2-ones with antitumor effects5? ;Sulfur-free transition state nucleoside analog inhibitors of methylthioadenosine nucleosidase and phosphorylase6
Check Digit Verification of cas no
The CAS Registry Mumber 35166-78-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,1,6 and 6 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 35166-78:
(7*3)+(6*5)+(5*1)+(4*6)+(3*6)+(2*7)+(1*8)=120
120 % 10 = 0
So 35166-78-0 is a valid CAS Registry Number.
InChI:InChI=1/C7H13.BrH.Mg/c1-7-5-3-2-4-6-7;;/h7H,1-6H2;1H;/q;;+1/p-1/rC7H13BrMg/c8-9-6-7-4-2-1-3-5-7/h7H,1-6H2
35166-78-0Relevant articles and documents
SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF
-
Paragraph 0084, (2016/11/17)
A synthesis method for L-cyclic alkyl amino acid and a pharmaceutical composition having the said amino acid are provide in the present disclosure provides. The synthesis method comprises: step A.) preparing a cyclic alkyl keto acid or a cyclic alkyl keto acid salt having Structural Formula (I) or Structural Formula (II), and step B.) mixing the cyclic alkyl keto acid or the cyclic alkyl keto acid salt with ammonium formate, a leucine dehydrogenase, a formate dehydrogenase and a coenzyme NAD+, and carrying out a reductive amination reaction to generate the L-cyclic alkyl amino acid, wherein the Structural Formula (I) is where n1≧1, m1≧0 and the M1 is H or a monovalent cation; the Structural Formula (II) is where n2≧0, m2≧0, the M2 is H or a monovalent cation, an amino acid sequence of the leucine dehydrogenase is SEQ ID No.1.
GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
-
Page/Page column 54, (2010/02/15)
The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
